5/4/2021 12:45:28 PM - Perched at its all-time high following a Special Dividend and M&amp;A news with Thermo Fisher Scientific Inc (TMO) on 4/15/21. Reported Mar &#39;21 quarterly earnings +59% on +29% sales revenues versus the year-ago period. Quarterly earnings were above the +25% minimum guideline (C criteria) in the 3 latest comparisons. Found support at its 200 DMA line since noted with caution in the 9/24/20 mid-day report after pricing a Secondary Offering. Limited history since its $27 IPO on 2/06/20.<br><hr>4/23/2021 12:43:00 PM - Perched at its all-time high following a Special Dividend and M&amp;A news with Thermo Fisher Scientific Inc (TMO) on 4/15/21. Reported Dec &#39;20 quarterly earnings +50% on +30% sales revenues versus the year-ago period. Quarterly earnings were above the +25% minimum guideline (C criteria) in 3 of the 4 latest comparisons. Found support at its 200 DMA line since noted with caution in the 9/24/20 mid-day report after pricing a Secondary Offering. Limited history since its $27 IPO on 2/06/20.<br><hr>4/22/2021 1:14:23 PM - Perched at its all-time high following a Special Dividend and M&amp;A news with Thermo Fisher Scientific Inc (TMO) on 4/15/21. Reported Dec &#39;20 quarterly earnings +50% on +30% sales revenues versus the year-ago period. Quarterly earnings were above the +25% minimum guideline (C criteria) in 3 of the 4 latest comparisons. Found support at its 200 DMA line since noted with caution in the 9/24/20 mid-day report after pricing a Secondary Offering. Limited history since its $27 IPO on 2/06/20.<br><hr>4/21/2021 1:01:15 PM - Perched at its all-time high following a Special Dividend on 4/15/21. Reported Dec &#39;20 quarterly earnings +50% on +30% sales revenues versus the year-ago period. Quarterly earnings were above the +25% minimum guideline (C criteria) in 3 of the 4 latest comparisons. Found support at its 200 DMA line since noted with caution in the 9/24/20 mid-day report after pricing a Secondary Offering. Limited history since its $27 IPO on 2/06/20.<br><hr>4/16/2021 1:27:55 PM - Perched at its all-time high following a Special Dividend. Reported Dec &#39;20 quarterly earnings +50% on +30% sales revenues versus the year-ago period. Quarterly earnings were up above the +25% minimum guideline (C criteria) in 3 of the 4 latest comparisons. Last noted 9/24/20 after pricing a Secondary Offering. Limited history since its $27 IPO on 2/06/20.<br><hr>9/24/2020 12:31:17 PM - Consolidating above its 50 DMA line ($32.15) after pricing a Secondary Offering last week.  Reported Jun &#39;20 quarterly earnings -4% on +1% sales revenues versus the year-ago period. Quarterly sales revenues and earnings should be up +25% or more and ideally accelerating over prior quarters.<br><hr>9/21/2020 12:29:04 PM - Consolidating above its 50 DMA line ($31.80) after pricing a Secondary Offering last week.  Reported Jun &#39;20 quarterly earnings -4% on +1% sales revenues versus the year-ago period. Quarterly sales revenues and earnings should be up +25% or more and ideally accelerating over prior quarters.<br><hr>9/18/2020 12:18:26 PM - Consolidating above its 50 DMA line ($31.70) after pricing a Secondary Offering this week.  Reported Jun &#39;20 quarterly earnings -4% on +1% sales revenues versus the year-ago period. Quarterly sales revenues and earnings should be up +25% or more and ideally accelerating over prior quarters.<br><hr>9/17/2020 12:20:06 PM - Consolidating above its 50 DMA line ($31.60) after pricing a Secondary Offering.  Reported Jun &#39;20 quarterly earnings -4% on +1% sales revenues versus the year-ago period. Quarterly sales revenues and earnings should be up +25% or more and ideally accelerating over prior quarters.<br><hr>9/10/2020 1:22:10 PM - Reported Jun &#39;20 quarterly earnings -4% on +1% sales revenues versus the year-ago period. Quarterly sales revenues and earnings should be up +25% or more and ideally accelerating over prior quarters.<br><hr>9/9/2020 12:40:13 PM - Reported Jun &#39;20 quarterly earnings -4% on +1% sales revenues versus the year-ago period. Quarterly sales revenues and earnings should be up +25% or more and ideally accelerating over prior quarters.<br><hr>6/11/2007 12:43:24 PM - Sales history are below the guidelines. Quarterly sales should also be up 25% or more or accelerating over prior quarters.<br><hr>6/8/2007 12:21:50 PM - Sales history are below the guidelines. Quarterly sales should also be up 25% or more or accelerating over prior quarters.<br><hr>6/6/2007 12:32:28 PM - Sales history are below the guidelines. Quarterly sales should also be up 25% or more or accelerating over prior quarters.<br><hr>7/11/2005 12:53:48 PM - Continues advancing after recent BO from long flat base. Too ET.<br><hr>